801 related articles for article (PubMed ID: 24142395)
1. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
[TBL] [Abstract][Full Text] [Related]
4. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
6. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
[TBL] [Abstract][Full Text] [Related]
7. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
8. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.
Cherenfant J; Stocker SJ; Gage MK; Du H; Thurow TA; Odeleye M; Schimpke SW; Kaul KL; Hall CR; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA; Talamonti MS
Surgery; 2013 Oct; 154(4):785-91; discussion 791-3. PubMed ID: 24074416
[TBL] [Abstract][Full Text] [Related]
9. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
Sallinen V; Haglund C; Seppänen H
Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor.
Nanno Y; Matsumoto I; Zen Y; Otani K; Uemura J; Toyama H; Asari S; Goto T; Ajiki T; Okano K; Suzuki Y; Takeyama Y; Fukumoto T; Ku Y
Ann Surg Oncol; 2017 Apr; 24(4):1127-1133. PubMed ID: 27822631
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
13. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
[TBL] [Abstract][Full Text] [Related]
15. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
[TBL] [Abstract][Full Text] [Related]
16. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
[TBL] [Abstract][Full Text] [Related]
18. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
20. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification.
Raverot G; Dantony E; Beauvy J; Vasiljevic A; Mikolasek S; Borson-Chazot F; Jouanneau E; Roy P; Trouillas J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3368-3374. PubMed ID: 28651368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
